Last viewed: ENLV


Prices are updated after-hours



nasdaq:ENLV Enlivex Therapeutics Ltd.

ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-16.0% 1m) (-56.5% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (Infinity% volume)
Earnings Calendar: 2022-08-08
Market Cap: $ 80,692,818

http://www.enlivex.com
Sec Filling | Patents | n/a employees


Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

sclerosis   cancer   autoimmunity   israel   multiple sclerosis   car-t   rheumatoid arthritis   bone   treatment   cancer treatments  

add to watch list email alert is off

Press-releases


Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
Published: 2022-10-03 (Crawled : 12:20) - globenewswire.com
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -4.13% H: 5.98% C: 0.48%


Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
Published: 2022-09-12 (Crawled : 14:00) - biospace.com/
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 4.49% H: 3.52% C: 2.93%

preclinical
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 4.46% H: 0.0% C: -7.24%

patent for application therapy
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
Published: 2022-08-29 (Crawled : 13:20) - biospace.com/
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

patent for application
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Published: 2022-08-24 (Crawled : 12:20) - globenewswire.com
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 16.48% C: 11.17%

clearance expansion integration for trial
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
JNJ | News | $165.62 1.48% -0.34% | twitter stocktwits trandingview |
Health Technology
| | O: 1.1% H: 0.0% C: 0.0%
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -4.79% H: 14.26% C: 10.9%

update results
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
Published: 2022-08-17 (Crawled : 13:00) - biospace.com/
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 1.94% H: 0.29% C: -1.33%

for health trial approval
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
Published: 2022-08-03 (Crawled : 12:20) - globenewswire.com
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 4.39% H: 7.15% C: 5.31%

patent for application
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Published: 2022-07-06 (Crawled : 13:00) - globenewswire.com
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 6.31% H: 8.35% C: 2.2%

trial
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Published: 2022-06-06 (Crawled : 19:00) - biospace.com/
ENLV | $4.39 4.52% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: -0.19% H: 1.75% C: -0.39%

for health trial authorization
See all


Last 15 days Sec forms
File Id Form Published Date Transaction Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Top 10 Gainers
VEV | $1.07 5.42% 59.81% | twitter stocktwits trandingview |
Manufacturing

HCKT | News | $19.22 4.86% 49.17% | twitter stocktwits trandingview |
Commercial Services

PEGY J | $1.43 79.69% 30.77% | twitter stocktwits trandingview |
Manufacturing

TOPS | $5.43 66.05% 25.23% | twitter stocktwits trandingview |
Transportation

AREB | $0.4294 19.28% 18.77% | twitter stocktwits trandingview |
Manufacturing

UNCY | $0.5559 -7.35% 16.93% | twitter stocktwits trandingview |
Professional, Scientific, and T...

SABS | $0.77 2.68% 16.88% | twitter stocktwits trandingview |

ALYA | $1.97 3.14% 16.5% | twitter stocktwits trandingview |
Technology Services

STSS 4 | $1.3 10.17% 16.15% | twitter stocktwits trandingview |
n/a

LIQT | $0.3901 0.54% 15.35% | twitter stocktwits trandingview |
Producer Manufacturing


Last 48 Hours Insiders Buying
UTG P 400 | $34.13 0% | twitter stocktwits trandingview |
Miscellaneous
| 18:00

12 months watchlist earnings calendar